Ergomed Notice of AGM and Annual Report
13/05/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220513:nRSM3649La&default-theme=true
RNS Number : 3649L Ergomed plc 13 May 2022
Notice of AGM and Annual Report
Guildford, UK - 13 May 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, announces that its Annual General Meeting ("AGM")
will be held at 1 Cornhill, London, EC3V 3ND at 9:30 a.m. on Friday, 10 June
2022.
Ergomed's Annual Report and Accounts for the year ended 31 December 2021,
Notice of AGM and Form of Proxy will be available on the Company's website
at www.ergomedplc.com (http://www.ergomedplc.com/) and are being mailed to
its shareholders today.
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis
Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP
Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic
Communications
Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal
ergomed@consilium-comms.com (mailto:ergomed@consilium-comms.com)
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NOAATMMTMTBBTPT